Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.

Axcrona K, Aaltomaa S, da Silva CM, Ozen H, Damber JE, Tankó LB, Colli E, Klarskov P

BJU international13 Apr 2012Cited by 81 (Europe PMC)

PMID22500884DOI10.1111/j.1464-410x.2012.11107.xPepBankPUB-22500884

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In prostate cancer patients, prostate volume changes were similar with degarelix and goserelin plus bicalutamide (-37.2% versus -39.0%), meeting non-inferiority.
In plain wordsIn prostate cancer patients, prostate volume reductions were similar with degarelix and goserelin plus bicalutamide.
Peptide
Degarelix
Outcome
No significant changeTotal prostate volume change
Study
n = 175
Comparator
Goserelin plus initial bicalutamide
Analysis
Primary
Outcome group
Tumor growth · Kidney and urinary
Studied dose
240/80 mg monthly · 12 weeksAs given in this study (human).
Measurements
Prostate volume change
−37.2%
degarelix
Prostate volume change
−39%
goserelin
Source sentences
Summary
At week 12, changes in TPV for degarelix and goserelin were similar (-37.2% vs -39.0%) and met the predefined non-inferiority criterion.
1 context sentence(design, population, supporting numbers)
Summary · context
• This was a randomized, parallel-arm, active-controlled, open-label, multicentre trial on 182 patients treated with either monthly degarelix (240/80 mg) or goserelin (3.6 mg) for 12 weeks. • For flare protection, goserelin-treated patients also received daily bicalutamide (50 mg) during the initial 28 days.
Report a problemFND-2250088401
02HumanRandomized controlled trialEfficacy outcome
In prostate cancer patients, IPSS responses occurred in 61.0% with degarelix versus 44.3% with goserelin plus bicalutamide (P = 0.02).
In plain wordsIn prostate cancer patients, more patients had urinary symptom responses with degarelix than goserelin plus bicalutamide.
Peptide
Degarelix
Outcome
IncreaseIPSS change of at least three points
Study
n = 175
Comparator
Goserelin plus initial bicalutamide
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
240/80 mg monthly · 12 weeksAs given in this study (human).
Measurements
IPSS response
61%
degarelix
IPSS response
44.3%
goserelin
Source sentences
Summary
The number of patients with an IPSS change of ≥ 3 over baseline was also significantly higher in patients treated with degarelix (61.0 vs 44.3%, P = 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
• This was a randomized, parallel-arm, active-controlled, open-label, multicentre trial on 182 patients treated with either monthly degarelix (240/80 mg) or goserelin (3.6 mg) for 12 weeks. • For flare protection, goserelin-treated patients also received daily bicalutamide (50 mg) during the initial 28 days.
Report a problemFND-2250088403
03HumanRandomized controlled trialEfficacy outcome
In symptomatic prostate cancer patients, IPSS fell more with degarelix than goserelin plus bicalutamide (-6.7 ± 1.8 versus -4.0 ± 1.0; P = 0.02).
In plain wordsIn symptomatic prostate cancer patients, degarelix reduced urinary symptoms more than goserelin plus bicalutamide.
Peptide
Degarelix
Outcome
DecreaseIPSS decrease with baseline IPSS above thirteen
Study
n: not reported in source
Comparator
Goserelin plus initial bicalutamide
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
240/80 mg monthly · 12 weeksAs given in this study (human).
Measurements
IPSS change
−6.7 points
degarelix, baseline IPSS > 13
IPSS change
−4 points
goserelin, baseline IPSS > 13
Source sentences
Summary
Decreases in IPSS were greater in degarelix than in goserelin-treated patients, differences being statistically significant in patients with baseline IPSS > 13 (-6.7 ± 1.8 vs -4.0 ± 1.0; P = 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
• This was a randomized, parallel-arm, active-controlled, open-label, multicentre trial on 182 patients treated with either monthly degarelix (240/80 mg) or goserelin (3.6 mg) for 12 weeks. • For flare protection, goserelin-treated patients also received daily bicalutamide (50 mg) during the initial 28 days.
Report a problemFND-2250088402
04HumanRandomized controlled trialSafety outcome
In prostate cancer patients, degarelix and goserelin plus bicalutamide were both reported as safe and well tolerated.
In plain wordsIn prostate cancer patients, degarelix and goserelin plus bicalutamide were both reported as safe and well tolerated.
Peptide
Degarelix
Outcome
Not applicableSafety and tolerability
Study
n: not reported in source
Comparator
Goserelin plus initial bicalutamide
Outcome group
Adverse events · Whole body
Studied dose
240/80 mg monthly · 12 weeksAs given in this study (human).
Source sentences
Summary
Both treatments were safe and well tolerated.
1 context sentence(design, population, supporting numbers)
Summary · context
• This was a randomized, parallel-arm, active-controlled, open-label, multicentre trial on 182 patients treated with either monthly degarelix (240/80 mg) or goserelin (3.6 mg) for 12 weeks. • For flare protection, goserelin-treated patients also received daily bicalutamide (50 mg) during the initial 28 days.
Report a problemFND-2250088404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00884273

Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients

Ferring Pharmaceuticalsn = 182Aug 2009 to Mar 2011

Prostate Cancer

Trial page ClinicalTrials.govUpdated 13 Nov 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:35 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC